StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/304% below fair value
$29.94−0.54 (-1.76%)

Close on Nov 13, 2026Market cap $1.54BP/E –Yield 0.00%

Immunocore operating margin

Operating margin is operating income as a percentage of revenue.

Immunocore's operating margin for the twelve months ending Sep 30, 2026 was -6.8%. For fiscal 2025 it was -11.3%, against -22.7% the year before. The highest annual figure on record is -11.3% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-11.3%+11.4
FY2024Dec 31, 2024-22.7%+1.2
FY2023Dec 31, 2023-23.9%+5.7
FY2022Dec 31, 2022-29.7%+448.9
FY2021Dec 31, 2021-478.5%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-13.3%−6.4
Q2 FY2026Jun 30, 2026-2.6%+12.6
Q1 FY2026Mar 31, 20266.8%+10.7
Q4 FY2025Dec 31, 2025-18.8%+4.3
Q3 FY2025Sep 30, 2025-6.9%+3.7
Q2 FY2025Jun 30, 2025-15.2%+6.1
Q1 FY2025Mar 31, 2025-3.9%+33.7
Q4 FY2024Dec 31, 2024-23.1%+1.2
Q3 FY2024Sep 30, 2024-10.6%+11.2
Q2 FY2024Jun 30, 2024-21.2%+1.8
Q1 FY2024Mar 31, 2024-37.6%−10.7
Q4 FY2023Dec 31, 2023-24.3%–
Q3 FY2023Sep 30, 2023-21.8%–
Q2 FY2023Jun 30, 2023-23.0%–
Q1 FY2023Mar 31, 2023-26.9%–

More Immunocore figures

See a number that looks wrong?